Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Imitrex Prescribers (US)

Articles with lock require a subscription to GLG News | Request a free trial
November 26, 2007
Taisho/Pfizer’s TS-032 for Schizophrenia: A New Player in mGluR Field
Analysis of: Taisho and Pfizer Sign a Letter of Intent for Taisho's Schizophrenia Drug Candidate | biz.yahoo.com
Author: GLG Expert Contributor
Pfizer has tentatively agreed to partner with Taisho to develop and commercialize the new schizophrenia drug TS-032 outside Japan.  This move may support Pfizer’s efforts to expand its share in the antipsychotic market beyond Geodon.
November 21, 2007
AstraZeneca’s Seroquel XR: Acute….Maintenance…What’s next?!
Analysis of: Seroquel XR Receives Approval From FDA for Maintenance Treatment of Schizophrenia | pharmalive.com
Author: GLG Expert Contributor
FDA has recently approved once-daily Seroquel XR for maintenance treatment of adult schizophrenia patients.  Risk of relapse and recurrence of acute psychotic symptoms were 84% less in patients receiving Seroquel XR vs. placebo.
September 18, 2007
Actelion’s Almorexant: More Hype than Hypnosis!
Analysis of: Actelion Sleep Aid Does Well | online.wsj.com
Author: GLG Expert Contributor
Acetlion recently reported that Almorexant, a selective orexin receptor antagonist, dose-dependently increased total sleep time in primary insomniacs when compared to placebo.
September 14, 2007
Eli Lilly May Dominate the Antipsychotic Market with LY2140023
Analysis of: Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds | www.pipelinereview.com
Author: GLG Expert Contributor
Eli Lilly reported that the prodrug mGluR2/3 agonist LY2140023 met all end points in a randomized, three-armed, double-blind, placebo controlled, 4-week proof-of-concept trial that enrolled schizophrenia patients.
August 22, 2007
Hydrocodone -- The Return of Hill Billy Heroin?
Analysis of: Painkiller Widely Abused in South | www.washingtonpost.com
Author: GLG Expert Contributor
The article describes the increase in hydrocodone abuse, especially in the Southern and Rural US.
August 21, 2007
Medical Tourism -- Bargain or Boondoggle?
Analysis of: American's Gamble for Bargain Surgery Abroad | www.medpagetoday.com
Author: GLG Expert Contributor
The article describes several examples of medical tourism with different motivations and risks involved.
August 17, 2007
Novel Experimental Approach to Gliomas
Analysis of: Oncoscience AG, the european partner of YM BioSciences, announces completion of patient enrollment in phase III brain cancer trial of nimotuzab | www.pipelinereview.com
Author: GLG Expert Contributor
The articel discusses Oncoscience AG, the european partner of YM BioSciences experimenal treatment for gliomas.  It is based on a monoclonal antibody to EGFR and is being tested in combination with other treatments including radiation.
August 16, 2007
New Myasthenia Treatment Makes Sense
Analysis of: New Treatment Boosts Muscle Function In Myasthenia Gravis | www.medicalnewstoday.com
Author: GLG Expert Contributor
The article reports on an open label study recently published in Neurology.  Apparently a new treatment (oral EN101 antisense) appears to be effective at improving muscle strength and reducing fatigue in people with MG. 
August 14, 2007
Wyeth’s Bifeprunox Bites the Dust
Analysis of: Wyeth's Schizophrenia Pill Is Rejected by U.S. FDA | www.bloomberg.com
Author: GLG Expert Contributor
The FDA requested more data to prove that Bifeprunox works in schizophrenia patients.   This is the second major blow to Wyeth in many weeks after the FDA requested additional trials to approve Pristiq for vasomotor symptoms.
August 13, 2007
New MS treatments to be based on genetic breakthrough?
Analysis of: Genetic breakthrough offers MS sufferers hope of new treatment | www.timesonline.co.uk
Author: GLG Expert Contributor
Two genes have been linked to an increased risk for the development of MS.  Several researchers speculate on the ipact this may have on future treatments.

Previous Page : 1 2 3 4 5 6 7 Next11 to 20 of 67

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T13:45:22.747